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Abstract
Background: Alcohol-based hand rub (ABHR) is widely used in both health and social facilities to prevent infection,
but it is not known whether supplying it for regular perinatal use can prevent newborn sepsis in African rural
homes. Our study piloted a cluster randomised trial of providing ABHR to postpartum mothers to prevent neonatal
infection-related morbidity in the communities.
Methods: We conducted a pilot parallel cluster randomised controlled trial across ten villages (clusters) in rural Eastern
Uganda. Pregnant women of over 34 weeks’ gestation were recruited over a period of 3 months. Both clusters received
the standard of care of antenatal health education, Maama Kit, and clinic appointments. In addition, women in the
intervention villages received ABHR, instructions on ABHR use, a poster on the ‘three moments of hand hygiene’, and
training. We followed up each mother-baby pair for 3 months after birth and measured rates of consent, recruitment,
and follow-up (our target rate was more than 80%). Other measures included ABHR use (the acceptable use was more
than four times a day) and its mode of distribution (village health workers (VHWs) or pharmacy), acceptability of study
protocol and electronic data capture, and the use of WHO Integrated Management of Childhood Illness (IMCI) tool to
screen for newborn infection.
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Results: We selected 36% (10/28) of villages for randomisation to either intervention or control. Over 12 weeks, 176
pregnant women were screened and 58.5% (103/176) were eligible. All, 100% (103/103), eligible women gave consent
and were enrolled into the trial (55 intervention and 48 control). After birth, 94.5% (52/55) of mothers in the intervention
and 100% (48/48) of mothers in the control villages were followed up within 72 h. Most, 90.9% (50/55), of the mothers in
the intervention villages (96.2% of live births) and 95.8% (46/48) of mothers in the control villages (95.9% of live births)
were followed up at 3months. In intervention villages, the average hand rub use was 6.6 times per day. VHWs accounted
for all ABHR stock, compared to the pharmacy that could not account for 5 l of ABHR. The screening tool was positive for
infection among a third of babies, i.e. 29.2% (14/48) in the intervention villages versus 31.4% (16/51) in the control villages.
VHWs completed the first four questions of IMCI screening tool with ease and accuracy. There were no adverse reactions
with the ABHR.
Conclusion: It is feasible to conduct a cluster-randomised controlled trial (cRCT) of the provision of ABHR to postpartum
mothers to prevent neonatal infection-related morbidity in the community in resource-poor settings. Our results indicate
that home recruitment promotes excellent follow-up and retention of participants in community trials. The intervention
was safe. This pilot study informed the substantial changes necessary in the larger cRCT, including a change in the
primary outcome to a composite outcome considering multiple methods of infection detection. A large BabyGel cluster
randomised controlled trial is now required.
Trial registration: ISRCTN67852437, registered March 02, 2015
Trial funding: Medical Research Council/WellcomeTrust/DfID (Global Health Trials Scheme)
Keywords: Infant sepsis, Infection, Morbidity alcohol-based hand rub, Mothers, Hand hygiene, BabyGel, Pilot trial
Background
Globally, 45% of deaths in children under 5 years occur in
the neonatal period [1–3] with nearly 90% occurring in
sub-Saharan Africa and South Asia [4–6]. In Uganda, the
neonatal mortality rate is 27 deaths per 1000 live births
and has not changed for the past decade while the
post-neonatal mortality rate is 16 deaths per 1000 live
births [7]. In Eastern Uganda, neonatal mortality is higher
than the country average at 34 per 1000 live births, [7–9],
with 77% presenting with infection-related symptoms [8].
Though pneumonia, diarrhoeal diseases, and sepsis are
the leading infectious causes of deaths in children under
5 years annually [1, 10], the neonatal cause-of-death dis-
tribution differs between the early (0–6 days of life) and
late (7–28 days of life) periods and varies with neonatal
mortality rate level. Preterm birth (40.8%) and intrapar-
tum complications (27.0%) account for most early neo-
natal deaths in all regions of the world while infections
cause nearly half of late neonatal deaths [2], the target
for this study. In Uganda, 33% of newborns present with
a fever, 9% with symptoms of acute respiratory infec-
tions, and 20% experience diarrhoea [7]. Most newborn
infections and deaths occur in the community and are
frequently unreported to the health sector [11].
Evidence shows that these infant infections are
diseases of poverty, associated with poor home environ-
ments, remoteness, hunger, undernutrition, and lack of
access to essential services [4, 5, 12]. Some infections are
transmitted directly from the mother’s genital tract at
the time of birth, including streptococci, staphylococci,
and Escherichia coli [13], while most infections are
transmitted from toilets, animals, gardens, or other un-
clean areas through carers’ hands [14], resulting in neo-
natal tetanus, skin infections, pneumonia, diarrhoea, or
septicaemia. The baby’s umbilical stump is a particular
risk especially with traditional practices that increase
chances of cord infection, such as the umbilical applica-
tion of baby powder, soil, or manure [15].
Handwashing with soap is a simple and sustainable
measure that results in a large reduction in hand contam-
ination, even when used with unclean water [16–18]. Birth
attendant and maternal handwashing have been associated
with reductions in neonatal mortality [19]. An estimated
40% reduction in neonatal sepsis deaths relate to newborn
care practices at home [20]. A systematic review con-
cluded that evidence for the effect of clean birth and post-
natal newborn care practices on neonatal mortality was of
low quality [20]. The importance of handwashing in pre-
venting infection-related deaths has led WHO to develop
guidelines for hand hygiene both within health care set-
tings and in the community [21–24]. However, studies
show widespread non-adherence to the household guide-
lines, often due to lack of water and or washing facilities.
Globally, less than 20% wash their hands after defecation
[25] compared to the only 10% in Uganda [26]. Uganda
thus ranks among the ten countries with the poorest
handwashing behaviour, and access to water is not guaran-
teed for many regions in the country including Mbale.
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An alternative could, therefore, be alcohol-based hand
rub (ABHR) which is produced locally in Uganda from
sugar cane. It costs only US$0.025 (£0.02) per cleansing
and is active against a broad range of Gram-positive and
Gram-negative aerobic bacteria, fungi, and enveloped and
non-enveloped viruses [14, 27] known to cause diarrhoea
and lower respiratory tract infections in early childhood.
ABHR requires no infrastructure and can be easily distrib-
uted to any recruited Ugandan household. It is also
quicker than handwashing with soap and has been
suggested to increase compliance [28, 29]. It is therefore
rapidly scalable, either by including it with birthing kits or
through its provision at the time of birth.
Although ABHR was added to the 19th WHO Model
List of Essential Medicines, in support for hand hygiene
[14, 30], there is insufficient evidence for the prevention
of infections in early infancy. No policies as yet recom-
mend the use of ABHR for routine community postnatal
prevention of newborn infections. In the BabyGel study,
we hypothesise that the addition of ABHR to birthing kits
would enable mothers to provide effective hand hygiene
for the first three postnatal months and lower the risk of
young infant infections.
This study was undertaken to pilot a cluster rando-
mised trial design for the provision of ABHR antenatally
for use by postpartum mothers and other baby carers in
the prevention of infection-related neonatal morbidity
and mortality in these rural communities. The feasibility
aims were as follows:
1. To assess whether village leaders and pregnant
women are willing to participate in the study
(criteria: a participation rate of at least 80%)
2. To test the integrity, feasibility, and acceptability
of the study protocol including questionnaires,
information sheets, data management systems, and
methods for the identification of community
neonatal infections (iterative assessment and
refinement of processes)
3. To evaluate the use of the WHO IMCI criteria for
a community screening of possible infection as a
primary outcome (criteria: assessment of the
completed IMCI screening tool).
4. To determine the locally appropriate mechanism for
the distribution of ABHR through a comparison of the
relative benefits of pharmacy-based and VHW-based
distribution mechanisms (an iterative assessment)
5. To assess whether participants use ABHR once
recruited into the BabyGel trial (acceptable criteria:
mean use of at least four times/day)
6. To assess the level of contamination between
intervention and control clusters (acceptable
criteria: mean alcohol hand rub use of more than
once a day in control clusters).
7. To estimate the intracluster correlation coefficient
to inform the sample size calculation for a large
cluster randomised controlled trial
Other published findings from the BabyGel pilot trial
include the acceptability of ABHR for community use
[31], the optimising informed consent for trial participa-
tion in Uganda [32], and the newborn moments of com-
munity hand hygiene [33].
Methods
Study design
In this feasibility study, we piloted an open two-arm par-
allel cluster randomised controlled trial of the provision
of ABHR to postpartum mothers to prevent neonatal
infection-related morbidity in the home. We used the
definitions and methodology for feasibility and pilot
studies as recommended in the ‘CONSORT 2010 state-
ment: extension to randomised pilot and feasibility trials’
[34]. The pilot trial was locally approved by the Mbale
Regional Hospital Institutional Review Committee
(REIRC IN–COM 011/2015), registered with the Uganda
National Council for Science and Technology, and
prospectively registered (ISRCTN67852437).
Criteria for site selection
The study village was selected if it had recorded at least
ten births within the past 3 months and had one or more
active VHWs and the village leaders committed to study
participation and implementation.
Meanwhile, the health centres were included if they
had participated previously in community trials or
research.
Study setting
The study was conducted in ten clusters (villages)
around two community health centres (health centre
three (HCIII) and health centre four (HCIV)). The HCIII
was surrounded by three control villages, while the
HCIV was surrounded by five intervention and three
control villages. The clusters were rural villages located
in Mbale region, Eastern Uganda. A map of the villages
surrounding the targeted community health centres in
Mbale district was reviewed by the research team in col-
laboration with the village health team workers (VHWs)
(Fig. 1). Ten villages were selected from a map of 28 vil-
lages (Fig. 2) if they were within the catchment area of
the participating community health centres, were not
served by another community health centre, and had a
village health worker.
Pilot randomisation
The ten villages were assigned to either intervention or
control by simple random sampling in a central office in
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Mbale in a 1:1 ratio by a person who did not draw the
map. This represented a variety of distances of villages
from each other, from market areas, from the health
centres, and from the control villages, thus allowing con-
tamination to be effectively assessed. It was not possible
to blind women, health workers, local council leaders, or
researchers, due to the nature of the intervention.
Cluster consent
After allocation, researchers met the local council
leader(s) of each village to seek consent for participation
of their village in the pilot trial and the pilot trial
allocation.
Study timeline
Villages were selected in November 2014, 9 months be-
fore recruitment of the first participant for appropriate
trial preparation purposes. The recruitment of partici-
pants into the trial was time bound. The research mid-
wives recruited eligible women for a period of 12 weeks
between August 2015 and November 2015, while each
individual woman together with her baby was followed
up in her home by research midwives until 12 weeks
after childbirth. The overall pilot trial follow-up of par-
ticipants continued until May 2016 when the last
mother-baby pair had their final study assessments at 12
weeks (90 days) after birth.
Participants’ selection criteria
Pregnant women were eligible for the study if they had a
pregnancy with an estimated gestation of over 34 weeks
during the recruitment period and were resident in the
participating villages. The exclusion criteria included
temporary visitors (defined as any pregnant mother
found as a visitor in the home and will not stay after-
ward). Other clinical criteria (e.g. malaria in pregnancy,
previous caesarean section) were not used as exclusion
criteria in this pilot study due to the nature of the
intervention.
Participant recruitment
Each village health worker (VHW) identified pregnant
women from his/her village by direct contact or
review of the village-specific monthly pregnancy and
Fig. 1 The village map showing the villages drawn and the distribution of participants in each village for the BabyGel pilot trial. A map of villages
around the community health facilities drawn locally. The 10 BabyGel study villages were selected from the above map. There is also a Google
Earth map showing the distribution of all the study participants from each respective village. Each number (e.g. 0412) is the assigned identifier for
a participant in her household. The first two digits of the number is a study village number (e.g. 04) and the preceding two digits represent the
consecutive number for each participant as recruited in each village. The first five (01 to 05) were intervention while the last five (06 to 10) were
control villages. This distribution of participants shows clearly the careful selection of villages to observe the effects of contamination in this study
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birth register. Also, midwives identified pregnant
women turning up for their antenatal clinics at the
two participating health facilities from the list of
study villages. The VHWs or facility midwives then
notified a member of the research team about the
potential participant. The research team then visited
the woman’s home to confirm eligibility, obtain
informed consent, and conduct detailed study-specific
assessments.
The research midwife screened each woman for eligi-
bility and established the gestational age using a gesta-
tional wheel and the self-reported last normal menstrual
period (LNMP) [35]. The research team recruited
eligible women into the pilot trial for a period of 12
Fig. 2 CONSORT diagram showing the flow of participants through each stage of the BabyGel pilot cluster randomised trial. This CONSORT flow
chart illustrates the screening and randomisation of clusters and the flow of participants in the study
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weeks. They provided informed consent for trial partici-
pation and follow-up. Those who declined were given the
Maama Kit, and their data was not included. The Maama
Kit was devised by the Ministry of Health in Uganda to
ensure childbirth is conducted in a clean environment.
The Maama Kit consists of basic supplies, i.e. sterile
gloves, plastic sheets, cord ligature, razor blades, tetracyc-
line, cotton, gauze, soap, and sanitary pads [36].
Interventions: BabyGel intervention villages
Pregnant women in intervention villages were provided
with ABHR (Alsoft V, Saraya East Africa Co. Ltd.) at re-
cruitment. The recruiting research midwives provided
the ABHR free of charge to each woman in a 1-l bottle
for use while at home, along with a refillable 100-ml bot-
tle for use while travelling.
The recruiting midwives trained each woman in the
intervention villages on the use of ABHR, the basic hand
rub steps, and the ‘three moments for community neo-
natal hand hygiene’ (Fig. 3), developed by the study team
for the pilot trial [33]. This was adopted from the WHO
‘5 Moments for Hand Hygiene’ [14]. The three moments
for community neonatal hand hygiene instructions were
printed on a poster with a pictorial illustration, which
was given to the participants as instructions to display in
a visible area and follow in their homes. The poster was
available in both English and the local language (Luma-
saba). The instructions on the poster recommended
hand rub before touching the baby, before clean or asep-
tic procedures by birth attendants, and daily wiping of
cord end with the ABHR three times a day until it falls
off. It also included, after any body fluid exposure risk
such as after the mother or carer using the toilet, touch-
ing any surfaces and exposure to child faeces. The mid-
wives encouraged women to apply the ABHR based on
this policy.
In addition to the training and the poster, the recruiting
research midwives provided further instructions to the
women. This included women commencing the ABHR at
the time of recruitment until 3 months after childbirth,
each woman performing a whole body wipe of the baby
with ABHR within 4 h of birth [37], and every woman
encouraging any carer or family member (including chil-
dren) to use the ABHR with the ‘three moments’ instruc-
tions used within and away from their homes.
The research midwives instructed women from three
of the five intervention villages to obtain refills from
their VHWs (VHW-based distribution) if the need arose,
while women from the other two intervention villages
refilled from the pharmacy at the health centre IV (phar-
macy-based distribution). This allowed us to compare
the two modes of ABHR distribution.
Alongside the above intervention, midwives offered
the current standard care practice (described below) as
was provided for the control villages.
After follow-up for the first 14 participants after birth
within the intervention clusters, we recognised that some
mothers reported forgetting to use the ABHR as indicated,
while some who had homebirths had not taken their new-
borns to the health facilities for immunisation. However,
Fig. 3 The ‘three moments for community neonatal hand hygiene’ poster developed for the BabyGel pilot trial. This shows an illustrative and
diagrammatic representation of the key moments of hand hygiene for newborns in the community
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in almost every household studied, there were already
school-going children present. We hence introduced a
system of the ‘expert child’ (a child in each house tasked
with the responsibility of reminding carers to use the
ABHR) to improve ABHR adherence and remind the
mother to notify the research team of any sick baby to
strengthen the multifaceted approach of the intervention.
In this pilot trial, we limited our communication to
the one-to-one teaching of the participants with the use
of the poster. This was a small-scale study in which the
behaviour change was limited to the participating
women and their immediate families. Mass communica-
tion or media strategies were, therefore, not necessary.
Control villages: current standard care practice
Women in the control villages received the current
standard care of Maama Kits for delivery and the usual
antenatal education. At the time of recruitment, the
recruiting midwives advised the women to deliver at
health facilities. The midwives encouraged women to at-
tend postnatal checks and immunisation clinics at 6–24
h, 1–2 weeks, 6 weeks, 10 weeks, and 14 weeks at the
nearby health facilities in line with the local guidelines
[38]. These visits also included information on the im-
portance of hand hygiene in line with WHO guidelines
[21] and promote the usual practice of ‘dry care’ of the
umbilical cord [39, 40]. The research midwives discour-
aged women in the control villages from applying any
local substances to the cord including home-made saline
but use ‘dry care’, keeping the cord clean and dry.
Trial follow-up procedures
At the end of baseline data collection, the follow-up
study visit dates for day 1 and day 90 were
auto-generated from the ODK system on the mobile
smartphone, based on the expected date of delivery.
These scheduled dates were written on the follow-up
cards which were given to mothers. On the actual
follow-up dates, the research assistant captured the exact
dates for day 1 and day 90 assessment on the follow-up
card. This enabled some women to remind or call the re-
search team to confirm if they were approaching day 90.
The day 90 follow-up schedule from the electronic system
guided the research team when to visit the woman.
The participant, health centre midwives, or VHWs
notified the research team of the birth immediately
after birth. The research team also monitored the
scheduled expected date of delivery and contacted the
participant regularly to see whether they had given
birth. The team then visited the woman to collect
data as soon as possible after birth. VHWs were en-
couraged to visit mothers in their homes twice weekly
in the first 4 weeks after birth, then once a week
thereafter. At each visit, VHWs were asked to
complete the WHO IMCI screening tool (Fig. 4). Ba-
bies with a positive WHO IMCI screen were referred
to the nearest participating health facility for assess-
ment. Meanwhile, mothers with concerns about their
babies were also advised to take their babies directly
to the health centres where they were screened for
infection using the WHO IMCI screening criteria and
assessed by a clinician. The research team was noti-
fied of any positive WHO IMCI screen by either the
VHW or participant or health facility midwife/clin-
ician. The paediatrician based at Mbale hospital was
available for consultation for any sick infants present-
ing at the community health facility and or being ad-
mitted. The research team continued to follow up
each woman and her baby(ies) until 90 days postna-
tally. The research team encouraged VHWs to remind
the mothers in intervention villages to use the ABHR
and return for refills as required. The research assis-
tants also encouraged the use of the ABHR during
any follow-up phone calls and on the day 1 follow-up
visit.
Outcome measurements
Pilot trial process outcomes
Electronic data capture system The research midwives
collected data using the Open Data Kit system (ODK;
University of Washington, USA) loaded onto handheld
Samsung Galaxy S4 mobile phones. The research team
carried these phones into the community for entering
data directly from the participants. After completion
by a research assistant, three approvers performed
quality checks (i.e. the data collected by the research
assistant was reviewed and approved by the study co-
ordinator followed by the co-investigator, then data
manager). Once approved, the data on the phone auto-
matically synchronised with the server at the Liverpool
School of Tropical Medicine either while in the com-
munity or upon return to the research office where
there was adequate Wi-Fi signal or internet. The
research team discussed the structure, content of the
questions, format, and font size of the text on the
ODK phone after every data collection visit.
Specific versions of questions were developed for
data collection at baseline, follow-up at day 1 and day
90 after birth, and any interim visit.
At baseline visit. The research midwife collected base-
line demographics, hand hygiene exposure, and current
obstetric history. The midwife also collected ABHR
details including quantity dispensed and how to obtain
the refill, for participants from the intervention clusters.
Day 1 follow-up visit data included maternal outcomes
(antenatal and intrapartum) and neonatal outcomes (age,
birth weight, IMCI screening for infection).
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Day 90 follow-up visit data included neonatal out-
comes (medical history, IMCI screening for infection),
hand hygiene practices, and ABHR use.
Participant-specific outcomes
Primary outcome The primary outcome was the num-
ber of positive infants on the WHO IMCI screening tool
[41, 42] with modifications informed by the YICSSG
algorithm [43]. The rates of infection were assessed ac-
cording to the study-specific neonatal and young infants’
outcomes screening algorithm (Fig. 5). The research
midwives assessed newborns in their homes at 1–2 days
and 3months postnatally and applied the WHO IMCI
screening tool. The research team encouraged the
VHWs to complete the WHO screening tool whenever
Fig. 4 Adapted WHO IMCI screening tool for infection. This tool was administered to newborns at particular encounters as a screening tool
for infection
Ditai et al. Pilot and Feasibility Studies            (2019) 5:49 Page 8 of 20
in contact with the mother-baby pair. Further, the re-
search team asked the staff at health facilities to
complete the WHO IMCI screening tool if the baby was
presented to the facility without notice of the study
team. Any baby screening positive for infection at these
visits was referred to Mbale hospital for appropriate
management by the paediatrician. The blood sample was
collected from all admitted babies in the hospital for
malaria blood smear, complete blood count, culture, and
sensitivity.
Secondary outcomes
Infection-related infant mortality These were sepsis
deaths in the first 90 days of life, assessed using verbal
autopsy [44]. Infant mortalities at 24 h, 7 days, 4 weeks,
and 3 months of life (all cause and infective) were
assessed.
Maternal quality of life at 3months after childbirth
The research midwife assessed every woman using
the WHO Quality of Life Scale Brief Version (WHO-
QOL-BREF 1998) [45]. This tool was translated into
the local language (Lumasaba) for use and validation
in this community.
ABHR use The research midwives recorded the volume
of ABHR dispensed to each participant on the e-data
capture system at the time of recruitment and at end of
study through review of the dispensing and accountabil-
ity logs. The staff at the health facility pharmacy and
VHW in intervention villages maintained dispensing and
accountability logs of ABHR distributed to participants.
The study team then conducted an inventory of the dis-
tributed ABHR to participants from the designated
health facility and the VHW’s home. At the last
follow-up visit, the research assistant measured the total
volume of the ABHR remaining in the bottles to estab-
lish the total volume of ABHR used by each participant.
Adverse events The research team collected data on
any adverse events related to the ABHR among the new-
borns. The research team reported any event to the
mother or child that required hospitalisation and was
life-threatening or a congenital abnormality as a severe
adverse event (SAE) irrespective as to whether it is ex-
pected or potentially related to the study intervention.
Risk of contamination The research midwives collected
data on the ABHR use and knowledge of ABHR, during
the follow-up of all mothers in the control villages.
Fig. 5 Illustration of the method for the identification of infection-related infant outcomes in the BabyGel pilot trial. Infants participating in the
study had the IMCI screening tool administered either at routine research visits or when their mothers brought them to participating hospitals or
health centres. The group who screened positive were referred to the paediatric team at Mbale Hospital for clinical care, and along with those
who died, composed the primary outcome for the study. Those who screened negative returned to the community. At the hospital, those who
had screened positive had both a clinical and bacterial diagnosis performed; these were collected as secondary outcomes
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Community advisory board
A community advisory board (CAB) was set up consisting
of a religious leader, a woman representative, a teacher, the
local council (LC) 1 chairperson, a VHW, a clinical officer,
a motorbike ambulance cyclist, a midwife, the health facility
in charge, a doctor, and the Mbale District health officer
(chair). Two CAB meetings were held; the first one imme-
diately after the start of the study and the last one at the
end of the study. During the meetings, the researchers
explored the views of these members about the study and
its interventions.
Sample size
The main objective of this pilot trial was to test the feasibil-
ity of providing ABHR antenatally for use by mothers and
other baby carers after birth to prevent infection-related
neonatal morbidity and mortality in the communities. As
this was a pilot trial designed to examine the methodo-
logical and procedural uncertainties of a future full-scale
trial, we did not undertake a formal sample size calculation.
Instead, the data collection period was time limited. With
an average of 3 to 4 deliveries per month in the study vil-
lages, in a 3-month pilot, therefore, we expected to recruit
90–120 women. This would allow us to assess background
infection rates among newborns which we could use for a
formal sample size calculation for the full cluster rando-
mised trial (since funded by European and Developing
Countries Clinical Trials Partnership (EDCTP)).
Data analysis
For this pilot trial, the samples were compared as if indi-
vidually randomised (i.e. ignoring possible clustering
within villages). The baseline characteristics of the study
mothers are summarised as mean values with their stand-
ard deviations and ranges for continuous measures, or as
frequency counts and corresponding percentages for cat-
egorical measures. Similar statistics are used to summarise
all outcome measures. As the study was primarily con-
cerned with determining the feasibility of providing ABHR
to prevent infection-related neonatal morbidity, the differ-
ences between the two arms are also presented alongside
their 95% confidence intervals (calculated using exact bi-
nomial methods for categorical measures). No formal stat-
istical comparisons (p values) were calculated. The
intracluster correlation coefficients (ICC) for possible
infant infections among infants at 3 months after birth
was also calculated.
Results
Acceptability of intervention
Cluster consent
All, 100% (10/10), local council leaders of the rando-
mised villages gave informed consent for the participa-
tion of their village in the study and study allocation.
Participants’ consent
All, 100% (103/103), eligible women gave individual
informed consent to participate in the BabyGel pilot
trial. However, one woman in the intervention village
withdrew her consent from the study after birth, due to
pressure from the husband about the ABHR.
Community advisory board
All, 100% (12/12), CAB members chaired by the District
Health office approved and accepted the pilot trial and
the intervention in this area.
Screening and recruitment outcome
Over a 3-month period from 20 August 2015 to 30
November 2015, 176 pregnant women were screened
and 103 met the eligibility from the 10 villages. All,
100% (103/103), eligible women were recruited into the
pilot trial. Of the 41.5% (73/176) excluded from the trial,
71 did not meet the inclusion criteria of gestation age
less than 34 weeks and 2 others had only visited the
homes for a temporary period. Of the 103 participants
recruited, 55 were allocated and received the BabyGel
intervention, while 48 were allocated and received the
usual care. Figure 2 shows the CONSORT flow diagram
for the study.
Demographics
The participants’ demographic characteristics are sum-
marised in Table 1. Both types of clusters were evenly
matched. The study participants were mostly married
(77.1% (37/48) for control compared to 78.2% (43/55)
for intervention). About half (45.8% (22/48) for control
compared to 56.4% (31/55) for intervention) did not
complete primary education level and were either house-
wives (47.9% (23/48) for control compared to 45.5% (25/
55) for intervention) or peasant farmers (37.5% (18/48)
for control compared to 36.4% (20/55) for intervention),
although those in the intervention villages were more
likely to have homes with tap water (either personal or
shared) and more likely to have no latrine (Table 1).
They generally lived in ‘mud and wattle’ houses with
mud floors (47.9% (23/48) for control compared to
45.5% (25/55) for intervention) and corrugated iron
roofs (87.5% (42/48) for control compared to 89.1% (49/
55) for intervention), and obtained water from a shared
tap or borehole (72.9% (35/48) for control compared to
90.9% (50/55) for intervention). Most (91.7% (44/48) for
control compared to 80.0% (44/55) for intervention)
used non-ventilated pit latrines without the facility for
handwashing. Despite this, over 80% of women reported
washing their hands more than 50% of times after either
urinating or defecating, with about 87% using soap and
water (87.5% (42/48) for control compared to 87.3% (48/
55) for intervention).
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Table 1 Demographic/background characteristics (baseline assessment)
Control group Intervention group Both groups combined
Sample size 48 55 103
Age (mean, s.d., range) 24.8 (5.6) [15–37] 25.0 (5.7) [15–38] 24.9 (5.7) [15–38]
Marital status
Single (n, %) 10 (20.8) 12 (21.8) 22 (21.4)
Married (n, %) 37 (77.1) 43 (78.2) 80 (77.7)
Widowed (n, %) 1 (2.1) 0 1 (1.0)
Highest level of education attained
No formal education (n, %) 2 (4.2) 1 (1.8) 3 (2.9)
Did not complete primary ed. (n, %) 22 (45.8) 31 (56.4) 53 (51.5)
Completed primary (PLE) (n, %) 16 (33.3) 15 (27.3) 31 (30.1)
Completed ordinary (UCE) (n, %) 4 (8.3) 5 (9.1) 9 (8.7)
Completed advanced (n, %) 3 (6.3) 2 (3.6) 5 (4.9)
Completed tertiary (n, %) 1 (2.1) 1 (1.8) 2 (1.9)
Primary occupation
Unemployed (n, %) 6 (12.5) 3 (5.5) 9 (8.7)
Housewife (n, %) 23 (47.9) 25 (45.5) 48 (46.6)
Student (n, %) 0 3 (5.5) 3 (2.9)
Peasant farmer (n, %) 18 (37.5) 20 (36.4) 38 (36.9)
Businesswoman (n, %) 0 2 (3.6) 2 (1.9)
Professional (n, %) 1 (2.1) 0 1 (1.0)
Other (n, %) 0 2 (3.6) (hotel management, teacher) 2 (1.9)
House roof type
Iron sheet (n, %) 39 (81.3) 52 (94.5) 91 (88.3)
Grass thatched (n, %) 9 (18.8) 3 (5.5) 12 (11.7)
House floor type (more than one response possible)
Mud (n, %) 42 (87.5) 49 (89.1) 91 (88.3)
Brick (n, %) 10 (20.8) 11 (20.0) 21 (20.4)
Cement/stone/tile (n, %) 5 (10.4) 6 (10.9) 11 (10.7)
Other (n, %) 1 (2.1) (bricks and mud) 0 1 (1.0)
The main water source for home
Open water well (n, %) 12 (25.0) 1 (1.8) 13 (12.6)
Piped and tapped to home (n, %) 1 (2.1) 4 (7.3) 5 (4.9)
Shared tap/borehole (n, %) 35 (72.9) 50 (90.9) 85 (82.5)
Type of latrine used in home
No latrine (use bushes) (n, %) 3 (6.3) 8 (14.5) 11 (10.7)
Non-ventilated pit (n, %) 44 (91.7) 44 (80.0) 88 (85.4)
Ventilated improved pit (VIP) (n, %) 1 (2.1) 3 (5.5) 4 (3.9)
If latrine, type of handwashing facility
No facility (n, %) 32 (71.1) 38 (80.9) 70 (76.1)
Near latrine (n, %) 13 (28.9) 4 (8.5) 17 (18.5)
Away from latrine (n, %) 0 5 (10.6) 5 (5.4)
Animals/poultry reared/kept (n, %) 45 (93.8) 51 (92.7) 96 (93.2)
Cows and goats (n, %) 35 (77.8) 37 (72.5) 72 (75.0)
Poultry (n, %) 41 (91.1) 49 (96.1) 90 (93.8)
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Only half (47.9% (23/48) for control compared to
54.5% (30/55) for intervention) of the pregnancies were
planned; however, all reported attending antenatal
clinics. Most women, who reported unplanned pregnan-
cies, wished to have had appropriate child spacing;
though, they were not using family planning.
Follow-up outcome
All, 100% (103/103), mothers in both clusters were
followed up immediately after birth either in their homes
or from health facilities. The majority of women had live
births (94.5% (52/55) in intervention compared to 100%
(491/48) in control) and the research midwife completed
the planned assessments for the immediate study visit
(day 1 after childbirth) study visit. Three women in
intervention clusters had stillbirths and did not have the
immediate assessment performed.
At three months (90 days) after birth, most mothers
with live babies were followed up and completed the
final assessment (90.9%, 50/55) mother-baby pairs in
intervention compared to (95.8%, 46/48) mothers with
(95.9%, 47/49) live babies in control villages. This
Table 1 Demographic/background characteristics (baseline assessment) (Continued)
Control group Intervention group Both groups combined
Other (n, %) 12 (26.7) 11 (21.6) 23 (24.0)
Pigs (n, %) 11 (24.4) 11 (21.6) 22 (22.9)
Ducks (n, %) 0 1 (2.0) 1 (1.0)
Rabbits (n, %) 1 (2.2) 0 1 (1.0)
Times (out of 10) hands washed when
Urinating (median[range]) 5 [0–10] 4 [0–10] 5 [0–10]
0 (n, %) 8 (16.7) 9 (16.4) 17 (16.5)
1–4 (n, %) 13 (27.1) 19 (34.5) 32 (31.1)
5–9 (n, %) 11 (22.9) 12 (21.8) 23 (22.3)
10 (n, %) 16 (33.3) 15 (27.3) 31 (30.1)
Defecating (median [range]) 10 [1–10] 10 [4–10] 10 [1–10]
0 (n, %) 0 0 0
1–4 (n, %) 9 (18.8) 1 (1.8) 10 (9.7)
5–9 (n, %) 12 (25.0) 9 (16.4) 21 (20.4)
10 (n, %) 27 (56.3) 45 (81.8) 72 (69.9)
Last 10 handwashes, used
Water alone (n, %) 6 (12.5) 7 (12.7) 13 (12.6)
Water and bar soap (n, %) 42 (87.5) 48 (87.3) 90 (87.4)
Pregnancy planned (n, %) 23 (47.9) 30 (54.5) 53 (51.5)
Existing medical conditions
Asthma (n, %) 2 (4.2) 0 2 (1.9)
Cardiac disease (n, %) 0 0 0
Coagulation disorder (n, %) 0 0 0
Congenital abnormalities (n, %) 0 0 0
Diabetes (type 2) (n, %) 1 (2.1) 0 1 (1.0)
High blood pressure (n, %) 0 0 0
Malaria (n, %) 6 (12.5) 14 (25.5) 20 (19.4)
Tuberculosis (n, %) 0 0 0
HIV
0 (n, %) 32 (66.7) 39 (70.9) 71 (68.9)
1 (n, %) 7 (14.6) 8 (14.5) 15 (14.6)
2 (n, %) 9 (18.8) 8 (14.5) 17 (16.5)
STD (n, %) 1 (2.1) 0 1 (1.0)
Other (n, %) 0 0 0
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follow-up rate is commensurate with our predetermined
acceptable follow-up criteria of above 80% both within
24 h and three months after birth. Of the seven women
not followed-up on day 90, three had stillbirths, one had
relocated to Kampala, one withdrew consent after child-
birth, and two had neonatal deaths (Fig. 2 and Table 2).
Birth outcomes
There were no major differences in clinical outcomes
between both types of clusters for mothers and babies
(Table 2). Spontaneous vaginal births were common in
both types of clusters with only two caesarean sections
in each arm. There were slightly more babies born at
health facilities in the intervention arm (78.4%, 40/51)
than the control arm (64.6%, 31/48), and the births were
assisted by a local nurse/midwife (84.0% (42/51) inter-
vention vs 79.2% (38/48) control) or doctors in case of
caesarean sections (4.0% (2/51) intervention vs 10.4% (5/
48) control). There were homebirths assisted by a rela-
tive, neighbour, while others were born en route to the
facility or in the traditional birth attendants’ homes.
Study protocol
Overall, the study protocol was feasible and acceptable;
minor adjustments were made as the pilot progressed
and errors were identified. The electronic data capture
worked well, except for one participant whose initials
changed during the follow-up visit which caused confu-
sion with another participant. The research assistants
believed that this error might have happened due to the
small size of the handheld mobile smartphone (Samsung
Galaxy S4). Three of the questions in the case report
form had their text gradually revised to improve on con-
text, which gradually improved data collection as the
study progressed. The research assistants and those per-
forming quality checks of the data (study coordinator,
co-investigator, and data manager) all had no login er-
rors onto the ODK smartphone system. Further, there
were no extra logins required for synchronising data; the
phone data automatically and easily synchronised when-
ever the phone connected to the internet.
ABHR distribution
There were more women assigned to receive ABHR re-
fills through the VHWs (70.9%; 39/55) than through the
pharmacy (29.1%; 16/55), thus explaining the increased
refills in that group (61.8% (34/55) compared to the
pharmacy 21.8% (12/55)) (Table 3). Fifty women received
a mean of two additional litres per participant (each re-
ceived 1.1 l at the start). The mean number of refills was
hence two with a mean volume of 3.1 l per participant.
The women in both modes of distribution who did not
return for a refill had stillbirths (three), had relocated
(three), or had withdrawn from the study (one).
VHWs were very systematic and accurately accounted
for all the ABHR using the dispensing logs, compared to
pharmacy workers who were unable to account for 5 l at
the end of the study. Informal enquiry into the under-
lying reasons revealed that there were five midwives dis-
pensing the ABHR at the pharmacy, and some midwives
would dispense without completing the dispensing logs.
Some pharmacy midwives also reported using the ABHR
for their routine care, and some mothers reported being
sent back from the pharmacy without a refill.
ABHR use
The average frequency of ABHR use in the 5 interven-
tion villages was 6.6 times per infant per day, but half
stopped using it for at least 3 days continuously during
the 3 months; most reported that they had simply forgot-
ten to use it (Table 3).
Risk of contamination (criteria: ABHR use in control sites
less once a day)
There was no routine postnatal ABHR use reported in
any of the control sites, except for one woman who was
provided with a chlorhexidine gel from her local health
facility. She had not applied it on the cord and was ad-
vised to use ABHR instead. A separate local study
started towards the end of the BabyGel pilot. In this
study, the health facility midwives provided chlorhexi-
dine gel to every woman delivering in their facilities and
advised mothers to apply the gel on the umbilical cord
until it dropped off.
Primary outcome
The a priori primary outcome was the rate of positive
infection screen using the WHO’s IMCI screening
criteria for infection (Table 4). The screening tool was
positive for infection among a third of babies, i.e. 29.2%
(14/48) in the intervention villages versus 31.4% (16/51)
in the control villages.
VHWs completed the first four questions of IMCI
screening tool with ease and accuracy (Fig. 4). However,
the VHWs had challenges counting the baby’s respira-
tory rate or taking body temperature, both of which
were recordable vital signs on the IMCI screening tool.
They either left those questions blank (with no record
entered) or filled a value that was wrong. Though they
found challenges in taking temperature and counting re-
spiratory rate and pulse rate, the VHWs made the judge-
ment of high temperature through a touch of the baby
with their palm and the fast breathing through experi-
ence or observation in the change of breathing from
usual normal and completed the yes or no boxes. Fur-
ther, the VHWs frequently did not attend to the mothers
to complete the screening tool according to the pro-
posed schedule in the protocol.
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Neonatal infection rate
Few babies actually had a clinical diagnosis of infection
made in the study health centres or hospital (control
16.7% (8/48) compared to the intervention 21.6% (11/
51); Table 4). The highest rates of identification of pos-
sible infant infection were through direct questioning of
mothers. A half of women in the intervention arm
(51.0%, 26/51) reported that their babies had suffered
infections compared to two fifths in the control arm
(39.6%, 19/48). Some babies received antibiotics from
the local pharmacies and private clinics (control 16.7%
(8/48) compared to intervention 27.5% (14/51)) but were
neither screened nor reported to the study facilities.
Overall, more than half (control 56.3% (27/48) compared
to the intervention 54.9% (28/51)) of babies had some
evidence of non-malaria infection either reported by
Table 2 Birth outcome (mother)
Control group Intervention group Difference (95% CI)
Sample size 48 55 103
Birth outcome
Singleton (n, %) 47 (97.9) 55 (100.) 2.1 (not calculable)
Twin (n, %) 1 (2.1) 0
Outcome at initial assessment
Baby/babies survived (n, %) 47 (97.9) 51 (92.7) − 5.2 (− 13.2:2.8)
Stillbirth (n, %) 0 3 (5.5)
Baby died within 24 h (n, %) 1 (2.1) 0 –
Mother withdrew consent (n, %) 0 1 (1.8)
Mother lost to follow-up after initial assessment (n, %) 0 1 (2.1) –
Baby died after 10 days (n, %) 1 (2.1) 0
Revised sample size for initial postnatal assessment 48* 51
Mode of birth
Spontaneous vaginal birth (n, %) 46 (95.8) 49 (96.1) 0.2 (− 7.5:8.0)
Caesarean section (n, %) 2 (4.2) 2 (3.9)
Place of birth
Home (n, %) 7 (14.6) 6 (11.8) − 2.8 (− 16.2:10.5)
En route (n, %) 2 (4.2) 1 (2.0) − 2.2 (− 9.0:4.6)
Health centre (n, %) 31 (64.6) 40 (78.4) 13.8 (− 3.8:31.5)
Hospital (n, %) 4 (8.3) 2 (3.9) − 4.4 (− 13.9:5.0)
Other (n, %) 4 (8.3) 2 (3.9) − 4.4 (− 13.9:5.0)
Person assisting birth (n, %) 48 (100.) 50 (98.0) − 2.0 (not calculable)
Relative (n, %) 6 (12.5) 9 (17.6) 5.5 (− 8.7:19.7)
Traditional birth attendant (n, %) 1 (2.1) 3 (6.0) 3.9 (− 3.8:11.6)
Nursing assistant (n, %) 1 (2.1) 0 − 2.1 (not calculable)
Midwife/nurse (n, %) 38 (79.2) 42 (84.0) 4.8 (− 10.5:20.2)
Other (n, %) 5 (10.4) 2 (4.0) − 6.4 (− 16.6:3.8)
Doctor 2 2 –
Neighbour 1 0 –
Retired midwife 1 0 –
Trained birth attendant 1 0 –
Sex of baby
Male (n, %) 21 (43.8) 22 (43.1) − 0.6 (− 20.2:18.9)
Female (n, %) 27 (56.3) 29 (56.9)
Birthweight Mean (s.d.) 3.3 (0.6) [2.0–4.5]1 3.4 (0.4) [2.8–4.6]2 0.11 (− 0.20:0.42) (p = 0.478)
1n = 25
2n = 24
*Mothers = 47, but as 1 mother had twin birth, babies = 48
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mothers, evidenced in medical records, confirmed in the
hospital, or screened positive on the WHO IMCI tool.
There was no corresponding data collected centrally
against which to compare. Only a half of all the sick ba-
bies had a positive IMCI screening tool (control 29.2%
(14/48) compared to the intervention 31.4% (16/51)).
Adverse events
There were no reported adverse reactions to the ABHR.
There were, however, 15 severe adverse events (SAEs)
unrelated to ABHR. These consisted of three stillbirths
and one baby born with a cleft lip and palate (which was
later repaired) in the intervention villages. In the control
villages, there were two neonatal deaths: one occurred
16 h after birth due to asphyxia and another at 9 days
after birth due to severe sepsis. The other SAEs were
prolonged hospitalizations in both clusters.
Verbal autopsy
There were five verbal autopsy assessments performed
by research midwives before all investigators reviewed
the completed assessment forms. One was an early neo-
natal death that occurred 16 h after birth, and the likely
cause of death was asphyxia with no signs or symptoms
of sepsis. However, in the late neonatal death that oc-
curred 9 days after birth, the autopsy revealed the cause
of death to be severe sepsis. The rest of the verbal aut-
opsies were performed on the three stillbirths, and no
cause of death was found.
Intracluster correlation coefficients
The intracluster correlation coefficients (ICC) for pos-
sible infant infection in the first 90 postnatal days using
the WHO IMCI screen were 0.238 in the control villages
versus 0.171 in the intervention villages, and 0.171 for
all clusters considered together. The corresponding
values for the composite measure of infection (anyone
with a positive screen, maternal report, or clinical diag-
nosis) were 0.179 in the control villages, 0.194 in the
intervention villages, and 0.180 for both clusters
together.
The important changes to the methods after pilot trial
commencement
The introduction of the expert children was an import-
ant change in the trial. These reinforced the mothers
and other carers or visitors to use ABHR based on the
three moments for hand hygiene poster. They further
Table 3 ABHR distribution in intervention villages (n = 5) with participants (N = 55)
Via VHW Via pharmacy Overall Difference (95% CI)
Villages assigned 60.0% (3/5) 40.0% (2/5) 100% (5/5) 20 (−67.7:107.7)
Women wished to receive refills (self-reported) 70.9% (39/55) 29.1% (16/55) 100% (55/55) 41.8 (15.4:68.2)
Women actually refilled (self-reported at follow-up) 65.5% (36/55)2 25.5% (14/55)3 90.9% (50/55) 40 (12.4:67.6)
ABHR volume dispensed to women (litres; mean, range) 3.7 (2.8:4.1) 2.5 (2.0: 3.1) 3.1 (2.0: 4.1) 1.2 (1.09:1.31)
ABHR use/day (self-reported; mean, range) 7.0 (6.0:10) 6.2 (5.0:8.1) 6.6 (6.0:10.0) 0.8 (04.46:1.14)
ABHR accountability
ABHR volume delivered (litres) 40 20 60 –
ABHR accounted for (litres) 40 15 55 –
1One village had one recruit, who had a stillbirth and did not do any ABHR refills
2Three mothers did not return for ABHR refills due to either stillbirth (1), study withdrawal (1), or relocation (1)
3Two mothers did not return for ABHR refills due to stillbirths (2)
Table 4 Infant infection outcomes
Primary outcome Control
group
Intervention
group
Difference (95% CI)
n = 48 n = 51
Screen positive on IMCI form at any point within 90 days after birth 14 (29.2%) 16 (31.4%) 2.2 (− 15.9:20.3)
Sepsis deaths 1 (2.1%) 0 − 2.1 (not
calculable)
Clinically diagnosed infection in health centre or hospital 8 (16.7%) 11 (21.6%) 4.9 (− 10.5:20.3)
Mother reported infant infection 19 (39.6%) 26 (51.0%) 11.4 (−8.1:30.9)
Infant received antibiotics 8 (16.7%) 14 (27.5%) 10.8 (− 5.4:26.9)
Infant was hospitalised 3 (6.3%) 6 (11.8%) 5.5 (− 5.7:16.7)
Total with any evidence of non-malaria infection (positive screen, maternal report, or clinical
diagnosis)
27 (56.3%) 28 (54.9%) − 1.3 (− 20.9:18.2)
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encouraged mothers to take their newborns to the
clinics for immunisation.
Our planned follow-up schedule was that research
team would only follow up participants on day 1 and
day 90 after birth. However, the research team often vis-
ited the mothers outside the planned follow-up schedule,
especially during recruitment of another eligible mother
or follow-up of other mothers after birth for their sched-
uled dates of study appointment within the same or
nearby village.
Discussion
This pilot trial demonstrated that it was feasible to con-
duct a cluster randomised controlled trial of antenatal
distribution of ABHR to prevent infections among new-
borns in the communities. The absence of any adverse
reactions suggests that ABHR was safe to the newborns
and communities. This pilot trial supports the conduct
of a larger cluster randomised controlled trial in regard
to cluster randomisation, village consent, screening,
recruitment, individual informed consent rates, high
fidelity, and acceptability of the ABHR intervention
which was far above the set predetermined acceptable
criteria of more than 80%. In this pilot trial, we demon-
strated the relevance of home recruitment in promoting
follow-up and retention of participants in community
trials. Recruiting participants from their homes, with the
GPS coordinates automatically captured onto the ODK
system, made follow-up of participants simple even by
another research assistant (who simply followed coordi-
nates). There was no loss to follow-up.
The well-established network of village health team
workers contributed to the ability to fully recruit preg-
nant women in this trial in each village. Only 176 preg-
nant women were required to be screened to fully
recruit into this pilot trial, which was 1.7 times the en-
rolled sample. This translates into achievable recruit-
ment rate for the large main cluster randomised
controlled trial in the region.
We have demonstrated how the use of the VHWs for
the distribution of ABHR refills worked efficiently. Com-
munity health workers have been demonstrated to be an
important bridge to health care in other studies [46, 47].
However, pharmacy distribution was difficult with some
mothers being refused ABHR and some ABHR missing
from the pharmacies.
The study, further, confirms the efficient use of the
ODK electronic data collection system in the field as
seen in other African studies [48].
The reportedly high handwashing rate at baseline in
both types of clusters could be explained by the behav-
ioural changes following the study information, and
possibly a cholera outbreak in the region that occurred
prior the recruitment period and might have left a num-
ber of people informed about the need for handwashing.
The pilot trial showed that not all pregnancies end up
into live births. Some ended up into stillbirths and neo-
natal deaths in these African settings in line with the
existing literature [2, 9, 49]. In the planned main cRCT,
considerations should be made to exclude stillbirths and
neonatal deaths from further follow-up after death due
to the sensitivity of their situation. Further, these women
might benefit from bereavement support services. There
is a value in supporting bereaved families through
neonatal death and beyond [50, 51].
The training of mothers in the intervention clusters to
use the ABHR based on the three moments for commu-
nity neonatal hand hygiene [33] was a novel part of this
pilot trial. It aimed at reinforcing the practice of hand
rub for critical moments in the newborn’s life. Related
training based on the WHO’s 5 Moments of Hand Hy-
giene has been reported to improve hand hygiene com-
pliance in the health facilities [28]. Future research
would include investigating the perspectives of women
and baby carers towards these three moments of hand
hygiene and whether this influences hand hygiene com-
pliance in the homes. This pilot provided useful practical
insights to explore further in the conduct of the main
trial. One example is the creation of an ‘expert child’
within the home to improve adherence to the interven-
tion. Though the expert children encouraged the use of
the ABHR by anyone handling the baby and reminded
the mother to take the baby to the health facility for im-
munisation and in the event of infant fever or any other
concerns, there is not enough evidence in support of
their effectiveness to promote home adherence to med-
ical interventions. We, hence, would propose exploring
this further in the main trial design and any other Afri-
can community settings. Peer mentors and support
groups have been found to improve adherence to HIV/
AIDS interventions in the adult population [52–55], but
it is not yet established whether the expert children
would have a related benefit in a large community hand
hygiene intervention.
The WHO IMCI screening tool was used in this pilot
trial to describe the primary outcome of newborn infec-
tion. The pilot trial revealed difficulties with the IMCI
screening tool as a measure of the primary outcome. It
was difficult for the VHWs to accurately and completely
fill the screening tool, with many of their screening
forms having the wrong or missing vitals for
temperature, pulse, and respiratory rate. Routinely, the
VHWs are not routinely trained in measuring these vital
signs and many have little formal education. In the fu-
ture trial, therefore, we recommended that the VHWs
complete as much of the screening tool as they could
and refer any suspected sick babies directly to the
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facilities where the screening tool would be accurately
completed by skilled health workers/midwives.
The screening tool also missed babies where the
mother sought care through informal routes such as
local pharmacies, drug shops, or private clinics with no
designated staff for the infection screening process. In
this economically deprived rural community, many
women take their babies for care at local pharmacies
and private clinics [56]. A reliance on the attendance of
babies at the government clinics for the primary out-
come, therefore, misses a number of infants with infec-
tion. For a future main trial, these difficulties could be
avoided by carefully providing good training of frontline
health workers in the use of the WHO IMCI criteria for
the detection of infection in young infants [57]. In other
settings, therefore, with better trained VHWs, the IMCI
may still be an appropriate outcome.
This was a small pragmatic intervention study which
is feasible to conduct, and its aim was not to cause last-
ing social change or implement a programme. However,
there is some evidence that the trial intervention may
have affected care-seeking behaviour. In the intervention
group, there was a doubling of the number of women re-
ceiving antibiotics for their babies or being hospitalised,
and more women reporting infant infection. Though this
is in line with the theory of behaviour change framework
[58], it could benefit exploring it further in the main
trial. In this open study, where women are having daily
contact with the intervention, it produces a daily re-
minder of the importance of reducing infection-related
morbidity in the babies. This could reduce
infection-related morbidity through preventative means
(for example increasing the frequency of handwashing
after toilet use) or by seeking earlier care for the infant
at the first sign of any fever or any other symptom.
However, it could also emphasise to women the danger
of infection and lead to an increase in care-seeking be-
haviour and antibiotic use. It is critical therefore to use
an objective outcome measure for all women. Use of the
IMCI screen as an outcome would have provided this as
it is independent of the stage of the illness and would
have partially negated the effect of early care seeking. Al-
ternatives would have been clinician-diagnosed or
microbiologically proven infection. These would have
had the same benefits but require massive resources.
Maternally reported infant antibiotic use may be an
alternative primary outcome and has the benefit of
picking up babies with infection, irrespective of where
care was sought. Although it is likely to overestimate
the rate of true infections (whether diagnosed by health
care worker or microbiologically), it reflects a mixture
of infection-related symptoms of the infants and mater-
nal care-seeking behaviour. It is also a very important
public health outcome given the actual and social cost
of antibiotic use. However, a move to antibiotic use
alone for the primary outcome measure would place
the study at risk of ascertainment bias as women in the
ABHR arm potentially seek care for their infants at an
earlier stage. This bias could be eliminated through the
use of a placebo hand rub in the control arm. This
would allow a change of design to an individualised
randomised trial, but there are obvious practical and
ethical difficulties with the design and use of a placebo
ABHR. Thus, we propose that, for the main trial, the
primary outcome is a composite of infant infections in
the first 90 days of life, defined as any one or more of
(i) diarrhoea; (ii) lower respiratory tract infections; (iii)
omphalitis; (iv) IMCI danger sign(s), all verified by
health worker; (v) hospitalisation; or (vi) death. Each of
the above composite items will also be secondary out-
comes in their own right. These are meaningful clinical
endpoints that are feasible to collect and are relatively
unambiguous [59]. These outcome measures for the
proposed main trial have been selected, to reflect the
diversity of detection methods for sepsis as learned
from the pilot trial. Each component of the primary
outcome measure will be individually interrogated to
ensure no illogical effects within the composite. Diar-
rhoea has long been regarded as a disease of poverty
and is closely associated with poor hand hygiene of
carers and unsanitary home environments. Lower re-
spiratory tract infections are commonly spread to in-
fants through droplets on hands (rather than by
aerosol). Both are therefore preventable with good hand
hygiene [4, 5, 60]. This would accelerate adoption and/
or optimization of prevention products for
poverty-related diseases in sub-Saharan Africa for use
in pregnant women, newborns, and/or children.
Sample size in this trial was time-bound to accommo-
date the number of participants who would ably be
followed up within the timelines of the 6 months.
The results of this pilot trial allow the sample size esti-
mation for a future cluster randomised controlled trial
comparing ABHR and usual care. The intracluster coef-
ficient (ICC) estimate from this pilot trial was 0.17 (95%
CI 0–0.65); however, a larger study reported ICC esti-
mates from five similar context cluster randomised trials
predominantly in the range 0.01 to 0.10 [61], which is
considered more realistic than the pilot trial ICC. We
hence propose to use this ICC instead of the pilot trial
one for the future trial. To detect a reduction in the in-
fection rate of ≥ 25% for control group rates down to
15% if ICC ≤ 0.01, or to detect a reduction in the infec-
tion rate of ≥ 33% for control group rates down to 5% if
ICC ≤ 0.001 with a 90% power, 5932 participants are re-
quired. We have hence ignored multiple births for this
calculation. This sample size should be achievable over a
2-year period of recruitment and across 72 villages. The
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sample size calculations are based on a primary endpoint
of severe infection, with estimated rates of 5–30%.
Limitations of the study
This pilot trial was limited in the estimate of potential
ABHR effect due to the small sample size, as one would
expect in a pilot and feasibility study [34, 62]. A larger
cRCT is needed to draw conclusions about the effect of
ABHR on the prevention of newborn infections in the
community.
Although research midwives and clinicians objectively
evaluated the newborns and mothers during the
face-to-face encounters, we were only able to use
self-reported assessments for a number of baseline vari-
ables and outcome measures. This included handwash-
ing practices, ABHR acceptability, use of ABHR, and
incidence of newborn infections from participants. This
may have led to subjective bias in a number of ways. We
assumed that women’s reports were correct and accurate
and that women used the ABHR correctly instead of
disposing it or using it for other purposes.
Conclusion
This pilot trial results suggest that it is feasible to conduct
a cluster randomised controlled trial (cRCT) of the
provision of ABHR to postpartum mothers for the preven-
tion of neonatal infection-related morbidity in the com-
munity in resource-poor settings. Our results indicate that
home recruitment promotes excellent follow-up and re-
tention of participants in community trials. This study
informed the substantial changes necessary in the larger
cRCT. Our study enabled us to calculate ICC for the sam-
ple size calculation of a future cRCT. We also recommend
a change in the primary outcome of our study to a com-
posite outcome considering multiple methods of infection
detection in a larger cRCT.
The intervention was safe, and a large BabyGel cluster
randomised controlled trial is now required.
Endnotes
1One mother had a pair of twins, hence more babies
(49) than mothers (48).
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